CD19 and diffuse large B-cell lymphoma: The impact of the occurrence of CD19-negative relapses in patients with DLBCL after CART19 therapy has been less studied, in part because lymph node biopsies at the time of relapse are difficult to obtain and the techniques regularly used to analyze for CD19 expression on tumors (e.g., immunohistochemistry) are unreliable.